Feedback
  • Corrigendum: Case Report: Durable response to immuno-chemotherapy in a…

Corrigendum: Case Report: Durable response to immuno-chemotherapy in a case of ROS1 fusion-positive advanced lung adenocarcinoma: A case report

Affiliation
Department of Medical Oncology ,The First Affiliated Hospital of Zhengzhou University ,Zhengzhou ,China
Yan, Ningning;
Affiliation
Department of Medical Oncology ,The First Affiliated Hospital of Zhengzhou University ,Zhengzhou ,China
Huang, Siyuan;
Affiliation
Department of Medical Oncology ,The First Affiliated Hospital of Zhengzhou University ,Zhengzhou ,China
Li, Linlin;
Affiliation
Department of Medical Oncology ,The First Affiliated Hospital of Zhengzhou University ,Zhengzhou ,China
Guo, Qianqian;
Affiliation
Department of Medical Oncology ,The First Affiliated Hospital of Zhengzhou University ,Zhengzhou ,China
Geng, Di;
Affiliation
Department of Medical Oncology ,The First Affiliated Hospital of Zhengzhou University ,Zhengzhou ,China
Zhang, Huixian;
Affiliation
Department of Medical Oncology ,The First Affiliated Hospital of Zhengzhou University ,Zhengzhou ,China
Guo, Sanxing;
Affiliation
Department of Medical Oncology ,The First Affiliated Hospital of Zhengzhou University ,Zhengzhou ,China
Li, Xingya

Category

Published in:
Frontiers in Pharmacology
Vol. 14 (26.07.2023)
Volume:
14
Date Issued:
26.07.2023
DOI:
10.3389/fphar.2023.1256801
Language:
English
Type of Resource:
Text
Keywords:
immune checkpoint inhibitor; NSCLC; ROS1; chemo-immunotherapy; lung adenocarcinoma
Subject of DNB:
610 Medical sciences Medicine

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:
open graphic

Rights

License Holder: Copyright © 2023 Yan, Huang, Li, Guo, Geng, Zhang, Guo and Li.

Use and reproduction: